* Atea Pharmaceuticals Inc AVIR.OQ reported a quarterly
adjusted
loss of 10 cents per share for the quarter ended in September.
The mean expectation of four analysts for the quarter was for a
loss of 44 cents per share.
* Reported revenue was zero; analysts expected zero.
* Atea Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 10 cents.
* The mean earnings estimate of analysts had risen by
about 8.9%
in the last three months.
* In the last 30 days one analyst negatively revised an
earnings
estimate
* Atea Pharmaceuticals Inc shares had risen by 6.2% this
quarter and lost 32.4% so far this year.
* The company reported a quarterly loss of $8.07 million.
* Wall Street's median 12-month price target for Atea
Pharmaceuticals Inc is $8.00
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
This summary was machine generated from Refinitiv data November
7 at 10:58 p.m. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2022 -0.44 -0.10 Beat
Jun. 30 2022 -0.52 -0.38 Beat
Mar. 31 2022 -0.58 -0.51 Beat
Dec. 31 2021 0.17 1.34 Beat